medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 6

<< Back Next >>

Ann Hepatol 2014; 13 (6)

Role of SERPINB3 in hepatocellular carcinoma

Pontisso P

Language: English
References: 42
Page: 722-727
PDF size: 178.39 Kb.


ABSTRACT

SERPINB3 (formerly known as squamous cell carcinoma antigen-1 or SCCA1) is a member of the family of serine- protease inhibitors. SERPINB3 protects cells from oxidative stress conditions, but in chronic liver damage this serpin may lead to hepatocellular carcinoma through different strategies, including inhibition of apoptosis, induction of epithelial to mesenchymal transition and decrease of desmosomal junctions, cell proliferation and invasiveness. SERPINB3 may also contribute to tumor cell resistance to anti-neoplastic drugs through its binding to the respiratory Complex I, protecting cells from the pro-oxidant action of chemotherapeutic agents. Mechanisms of tumor growth promotion induced by SERPINB3 include the inhibition of intratumor infiltration of natural killer cells, up-regulation of Myc oncogene and the recent identification of this serpin as a Ras-responsive factor. In the liver SERPINB3 and SERPINBB4 isoforms (known as squamous cell carcinoma antigen or SCCA) are undetectable in normal hepatocytes, but their expression progressively increases in chronic liver diseases, dysplastic nodules and hepatocellular carcinoma. High SERPINB3 levels have been recently detected in HCC tissue of patients with early tumor recurrence after surgical resection. In serum SERPINB3/4 isoforms (or SCCA) are detectable bound to IgMs (SCCA-IgM) in the majority of HCV infected patients with HCC and in patients with cirrhosis their levels and/or the progressive increase have been found correlated to the risk of HCC development. Preliminary findings in patients with HCC revealed that SCCA-IgM was predictive of HCC prognosis, since low levels of this biomarker were able to identify HCC patients with long overall and progression-free survival.


REFERENCES

  1. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010; 78(Suppl. 1): 7-10. Pontisso P. , 2014; 13 (6): 722-727 726

  2. El-Serag HB, Kanwal F. Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go? Hepatology 2014. Doi: 10.1002/hep.27222 [Epub ahead of print].

  3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.

  4. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56: 769-75.

  5. Fattovich G. Epidemiology of hepatocellular carcinoma. J Hepatol 2003; 39(Suppl. 1): S50-S58.

  6. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.

  7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  8. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.

  9. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.

  10. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-92.

  11. Kato H. Expression and function of squamous cell carcinoma antigen. Anticancer Res 1996; 199616(4B): 2149-53.

  12. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL. Inhibition of apoptosis in human tumor cells by tumor-associated serpin, SCC antigen. Br J Cancer 2000; 82: 981-9.

  13. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun Rev 2009; 9: 108-12.

  14. Katagiri C, Nakanishi J, Kadoya K, Hibino T. Serpin squamous cell carcinoma antigen inhibits UV-induced apoptosis via suppression of c-JUN NH2-terminal kinase. J Cell Biol 2006; 172: 983-90.

  15. Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F, Kato H. Squamous cell carcinoma antigen suppresses radiation- induced cell death. Br J Cancer 2001; 84: 851-8.

  16. Ciscato, Sciacovelli M, Villano G, Turato C, Bernardi P, Rasola A, Pontisso P. SERPINB3 protects from oxidative damage by chemotherapeutics through inihibition of mitochondrial respiratory complex I. Oncotarget 2014; 5: 2418-27.

  17. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Valente M, Cannito S, et al. SERPINB3 induces epithelialmesenchymal transition. J Pathol 2010; 221: 343-56.

  18. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti- Furga G, Pawson T, et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997; 16: 706-16.

  19. Villano G, Turato C, Quarta S, Ruvoletto M, Ciscato F, Terrin L, Semeraro R, et al. Hepatic progenitor cells express SerpinB3. BMC Cell Biol 2014; 15: 5. Available at: http:// www.biomedcentral.com/1471-2121/15/5

  20. Villano G, Quarta S, Ruvoletto MG, Turato C, Vidalino L, Biasiolo A, Tono N, et al. Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. Int J Mol Med 2010; 25: 137-43.

  21. Suminami Y, Nagashima S, Muratami A, Nawata S, Gondo T, Hirakawa H, Numa F, et al. Suppression of Squamous Cell Carcinoma (SCC)-related serpin, SCC Antigen, inhibits tumor growth with increased intratumoral infiltration of killer cells. Cancer Res 2001; 61: 176-80.

  22. Turato C, Buendia MA, Fabre M, Redon MJ, Branchereau S, Quarta S, Ruvoletto M, et al. Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour? Eur J Cancer 2012; 48: 1219-26.

  23. Catanzaro JM, Sheshadri N, Pan JA, Sun Y, Shi C, Li J, Powers RS, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun 2014; 5: 3729. Doi: 10.1038/ncomms4729.

  24. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, et al. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005; 103: 2558-65.

  25. Guido M, Roskams T, Pontisso P, Fassan M, Thung SN, Giacomelli L, Sergio A, et al. Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol 2008; 61: 445-7.

  26. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004; 90: 833-7.

  27. Trerotoli P, Fransvea E, Angelotti U, Antonaci G, Lupo L, Mazzocca A, Mangia A, et al. Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol Cancer 2009; 8: 29. Doi: 10.1186/1476-4598-8-29.

  28. Villano G, Turato C, Quarta S, Ruvoletto M, Ciscato F, Terrin L, Semeraro R, et al. Hepatic progenitor cells express SerpinB3. BMC Cell Biol 2014; 15: 5. Available at: http:// www.biomedcentral.com/1471-2121/15/5.

  29. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 67-76.

  30. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006; 45: 1-4.

  31. Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, et al. SERPINB3 is associated with TGF-beta1 and cytoplasmic beta-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer 2014; 110: 2708-15.

  32. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta 2007; 383: 147-52.

  33. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.

  34. Silverman GJ. Regulatory natural autoantibodies to apoptotic cells: pallbearers and protectors. Arthritis Rheum 2011; 63: 597-602.

  35. Biasiolo A, Tono N, Zaninotto M, Merkel C, Fassina G, Plebani M, Gatta A, et al. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity. J Med Virol 2013; 85: 1005-8.

  36. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, et al. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008; 15: 246-9.

  37. Fransvea E, Trerotoli P, Sacco R, Bernabucci V, Milella M, Napoli N, Mazzocca A, et al. SCCA-IC serum levels are predictive of clinical response in HCV chronic hepatitis to an tiviral therapy: a multicentric prospective study. J Viral Hepat 2012; 19: 704-10.

  38. Giannini EG, Basso M, Bazzica M, Contini P, Marenco S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants’ serum levels in anti-HCV positive cirrhotic patients. J Viral Hepat 2010; 17: 563-8.

  39. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Beneduce L, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006; 119: 735-40.

  40. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, et al. Serum Scca-IgM as a predictor of hepatocellular carcinoma in patients with cirrhosis. O J Gas 2012; 2: 56-61.

  41. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.

  42. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, et al. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J Gastroenterol Hepatol 2014. Doi: 10.1111/ jgh.12576 [Epub ahead of print].




2020     |     www.medigraphic.com